Propyphenazone

Summary

Propyphenazone (CHEMBL28318) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC N02BB04); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BB04 (+2 more)
• Indications: 2 conditions
• Chemistry: 230.31 Da · C14H18N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL28318
Name	Propyphenazone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3778
ChEBI	CHEBI:135538
ATC	N02BB04, N02BB54, N02BB74
Molecular formula	C14H18N2O
Molecular weight	230.31
InChIKey	PXWLVJLKJGVOKE-UHFFFAOYSA-N

SMILES: CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(C)C

IUPAC name: 1,5-dimethyl-2-phenyl-4-propan-2-ylpyrazol-3-one

ChEBI definition: A pyrazolone derivative that is antipyrine substituted at C-4 by an isopropyl group.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, peripheral nervous system drug.

Also known as: Isopropylantipyrine, Propifenazona, Propyphenazone, Yoshipyrin, SID26758034, PROPYPHENAZONE, SID170465821, SID144205786, propyphenazone

Patent coverage: 1,203 distinct patent families (4,108 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5	Potency	10000	nM	CHEMBL_ACT_3625197

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).